Form 4: Karyopharm CMO's Stock Activity Post-PSU Vesting

Karyopharm Therapeutics' EVP & Chief Medical Officer, Reshma Rangwala, acquired shares from performance-based restricted stock unit vesting and subsequently sold a portion to cover tax liabilities.

Summary

• Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics Inc., acquired 945 shares of common stock on September 12, 2025.
• These shares represent performance-based restricted stock units (PSUs) granted in February 2023, which were earned due to the achievement of a clinical milestone: complete enrollment in the Company's Phase 3 SENTRY trial.
• The achievement of the clinical milestone was certified by the issuer's Compensation Committee on September 12, 2025, and the earned PSUs vested on the same date.
• Following the acquisition, Rangwala's beneficial ownership was 29,798 shares.
• On September 15, 2025, Rangwala disposed of 408 shares of common stock at a price of $6.43 per share.
• This sale was executed pursuant to a durable automatic sale instruction plan adopted on April 4, 2022, specifically to satisfy withholding tax liability incurred upon the PSU vesting.
• The sale was a broker-assisted transaction and not a discretionary trade by the reporting person.
• After the disposition, Rangwala's direct beneficial ownership stands at 29,390 shares.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of performance-based restricted stock units and a subsequent pre-planned sale to cover tax liabilities. While the PSU vesting indicates a positive clinical milestone achievement, the overall transaction is non-discretionary and does not reflect a change in management's sentiment or new strategic information.

Positives

• The vesting of performance-based restricted stock units (PSUs) indicates the successful achievement of a clinical milestone, specifically complete enrollment in the Phase 3 SENTRY trial.
• The Compensation Committee certified the achievement of the clinical milestone, demonstrating progress in the company's clinical development pipeline.

Negatives

• The reporting person disposed of 408 shares of common stock, reducing their direct beneficial ownership from 29,798 to 29,390 shares.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the implied progress from the SENTRY trial milestone.

Management Comments

• The sale does not represent a discretionary trade by the reporting person.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of performance-based restricted stock units (PSUs) and a subsequent tax-related sale. Such transactions are common in the biotechnology and pharmaceutical industries, where executive compensation often includes equity awards tied to clinical development milestones. The achievement of the Phase 3 SENTRY trial enrollment milestone is a positive indicator of progress in Karyopharm's clinical pipeline, aligning with industry trends of advancing drug candidates through late-stage trials.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor impact as it's a routine, pre-planned tax-related sale by an executive, not indicative of discretionary selling. The underlying PSU vesting signals progress in a key clinical trial.
• Employees: The vesting of PSUs for an executive may signal positive progress within the company's clinical development, potentially boosting morale.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones beyond the completion of the SENTRY trial enrollment.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary insider transaction where an executive acquired shares through the vesting of performance-based restricted stock units (PSUs) and subsequently sold a portion to cover tax obligations under a pre-existing 10b5-1 plan. While the vesting of PSUs is tied to the achievement of a clinical milestone (SENTRY trial enrollment), which is a positive operational update, the sale itself is not a discretionary action reflecting a change in the executive's view of the company's prospects. Therefore, this filing does not provide new information that would warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

Karyopharm Therapeutics, KPTI, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, PSUs, Clinical Trial, SENTRY trial, Biotechnology, Pharmaceuticals